Deliberate AI Announces its Depression and Anxiety Model, AI-COA™, is the First AI/ML Initiative to Be Accepted into the FDA’s ISTAND Pilot Program to Advance Drug Development
Digital Health Global
JANUARY 26, 2024
Under the program, Deliberate AI’s assessment tool for anxiety and depression, the AI-generated Clinical Outcome Assessment or AI-COA , will receive support to become a qualified drug development tool (DDT). Global experts have also expressed support for Deliberate AI’s innovative approach.
Let's personalize your content